A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma
A Phase I Open Label First in Human Dose Escalation of the immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination with Dexamethasone in Participants with Relapsed Refractory Multiple Myeloma
A multi-center, open-label, Phase 1b study to assess the pharmacokinetics, safety, and efficacy of subcutaneous and intravenous isatuximab (SAR650984) in combination with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma (RRMM)
A PHASE 1, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY OF BB2121 IN SUBJECTS WITH HIGH RISK, NEWLY DIAGNOSED MULTIPLE MYEL OMA (NDMM) (KarMMa-4)
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed / Refractory Multiple Myeloma (MM) Followed by a
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of BB2121 in Subjects with Multiple Myeloma (KarMMa-2)
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen) MASTER PROTOCOL
A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma
